In FDM models, CSA treatment mitigated refractive changes; downregulated c-Fos, IL-6, TNF-α, and NF-κB; and enhanced IL-10 expression [56], supporting its potential in inflammation-targeted myopia therapy, although further clinical validation is needed. Here, IL6 is linked to myopia.